Arne Kienzle

Dr. Arne Kienzle

Center for Musculoskeletal Surgery, Clinic for Orthopedics, Charité University Hospital Berlin, Berlin, Germany
orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 May 2017 in Advanced Healthcare Materials
Verified
Journal Article
Closed access
PDF file
Arne KienzleArne Kienzle
Arne Kienzle
SKSven Kurch
Sven Kurch
JSJanine Schlöder
Janine Schlöder
CBCarsten Berges
Carsten Berges
RORobert Ose
Robert Ose
HJHelmut Jonuleit
Helmut Jonuleit

1 October 2014 in Materials Science and Engineering: C
Verified
Journal Article
Closed access
ZFZhou Fang
Zhou Fang
YWYukun Wang
Yukun Wang
QFQingling Feng
Qingling Feng
Arne KienzleArne Kienzle
Arne Kienzle
Werner E.G. MüllerWerner E.G. Müller
Werner E.G. Müller

1 July 2014 in Journal of Biomedical Nanotechnology
Verified
Journal Article
Closed access
XLXujie Liu
Xujie Liu
WHWei He
Wei He
ZFZhou Fang
Zhou Fang
Arne KienzleArne Kienzle
Arne Kienzle
QFQingling Feng
Qingling Feng
Silver nanoparticles (Ag NPs) have been widely used in bone grafts due to their antimicrobial/antiviral properties. Despite extensive research focused on the cytotoxicity and genotoxicity of Ag NPs, little is known of their effect on cell differentiation. In this study, the uptake of Ag NPs and its effect on the osteogenic differentiation of human mensenchymal stem cells (hMSCs) were investigated in vitro. Ag NPs with a diameter of ∼30 nm were prepared. The hMSCs were exposed to different concentrations of Ag NPs, i.e., 0, 10, 50 and 100 μg/mL. The results show that Ag NPs cause cytotoxicity of hMSCs. It is also demonstrated that the uptake of Ag NPs does not affect the alkaline phosphatase activity, osteocalcin gene expression, osteopontin expression and mineralization level of hMSCs. The uptake of Ag NPs does not influence the osteogenic differentiation of hMSCs. This will give a positive reference for the application of Ag NPs in bone tissue engineering, especially their incorporation with stem cells in bone grafts.

1 May 2014 in Materials Science and Engineering: C
Verified
Journal Article
Closed access
YLY.S. Liu
Y.S. Liu
QHQ.L. Huang
Q.L. Huang
Arne KienzleArne Kienzle
Arne Kienzle
Werner E.G. MüllerWerner E.G. Müller
Werner E.G. Müller
QFQingling Feng
Qingling Feng

Verified
Journal Article
Open access
PDF file
Arne KienzleArne Kienzle
Arne Kienzle
MNMarcel Niemann
Marcel Niemann
SMSebastian Meller
Sebastian Meller
CGClemens Gwinner
Clemens Gwinner
Prior to undergoing total knee arthroplasty (TKA), surgeons are often confronted with patients with numerous questions regarding the procedure and the recovery process. Due to limited staff resources and mounting individual workload, increased efficiency, e.g., using artificial intelligence (AI), is of increasing interest. We comprehensively evaluated ChatGPT’s orthopedic responses using the DISCERN instrument. Three independent orthopedic surgeons rated the responses across various criteria. We found consistently high scores, predominantly exceeding a score of three out of five in almost all categories, indicative of the quality and accuracy of the information provided. Notably, the AI demonstrated proficiency in conveying precise and reliable information on orthopedic topics. However, a notable observation pertains to the generation of non-existing references for certain claims. This study underscores the significance of critically evaluating references provided by ChatGPT and emphasizes the necessity of cross-referencing information from established sources. Overall, the findings contribute valuable insights into the performance of ChatGPT in delivering accurate orthopedic information for patients in clinical use while shedding light on areas warranting further refinement. Future iterations of natural language processing systems may be able to replace, in part or in entirety, the preoperative interactions, thereby optimizing the efficiency, accessibility, and standardization of patient communication.

2 August 2018 in EMBO Molecular Medicine
Verified
Journal Article
Open access
PDF file
NSNevenka Dudvarski Stanković
Nevenka Dudvarski Stanković
FBFrank Bicker
Frank Bicker
SKStefanie Keller
Stefanie Keller
DJDavid Tw Jones
David Tw Jones
PHPatrick N Harter
Patrick N Harter
Mirko H.H. SchmidtMirko H.H. Schmidt
Mirko H.H. Schmidt
Glioblastoma (GBM) is a typically lethal type of brain tumor with a median survival of 15 months postdiagnosis. This negative prognosis prompted the exploration of alternative treatment options. In particular, the reliance of GBM on angiogenesis triggered the development of anti‐VEGF (vascular endothelial growth factor) blocking antibodies such as bevacizumab. Although its application in human GBM only increased progression‐free periods but did not improve overall survival, physicians and researchers still utilize this treatment option due to the lack of adequate alternatives. In an attempt to improve the efficacy of anti‐VEGF treatment, we explored the role of the egfl7 gene in malignant glioma. We found that the encoded extracellular matrix protein epidermal growth factor‐like protein 7 (EGFL7) was secreted by glioma blood vessels but not glioma cells themselves, while no major role could be assigned to the parasitic miRNAs miR‐126/126*. EGFL7 expression promoted glioma growth in experimental glioma models in vivo and stimulated tumor vascularization. Mechanistically, this was mediated by an upregulation of integrin α 5 β 1 on the cellular surface of endothelial cells, which enhanced fibronectin‐induced angiogenic sprouting. Glioma blood vessels that formed in vivo were more mature as determined by pericyte and smooth muscle cell coverage. Furthermore, these vessels were less leaky as measured by magnetic resonance imaging of extravasating contrast agent. EGFL7‐inhibition using a specific blocking antibody reduced the vascularization of experimental gliomas and increased the life span of treated animals, in particular in combination with anti‐VEGF and the chemotherapeutic agent temozolomide. Data allow for the conclusion that this combinatorial regimen may serve as a novel treatment option for GBM.